Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sustained-release methotrexate for intracavitary chemotherapy

E Chatelut1, P Suh, S Kim

  • 1University of California San Diego, Cancer Center, La Jolla 92093-0812.

Journal of Pharmaceutical Sciences
|March 1, 1994
PubMed
Summary

A novel slow-release formulation of methotrexate (Depo/methotrexate) demonstrated superior efficacy in a murine leukemia model. This lipid-based drug delivery system offers prolonged drug release and enhanced therapeutic benefits compared to standard methotrexate.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Off-label, but on target: the evidence needed to implement alternative dosing regimens of anticancer drugs.

ESMO open·2023
Same author

Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences·2018
Same author

Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?

The Journal of antimicrobial chemotherapy·2017
Same author

Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.

Pharmacological research·2016
Same author

Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.

Clinical pharmacology and therapeutics·2015
Same author

The scientific basis of body surface area-based dosing.

Clinical pharmacology and therapeutics·2014

Area of Science:

  • Pharmacology
  • Drug Delivery Systems
  • Oncology

Background:

  • Methotrexate is a widely used chemotherapy agent.
  • Standard methotrexate formulations have limitations in sustained release and therapeutic index.
  • Intracavitary administration requires formulations with prolonged local drug exposure.

Purpose of the Study:

  • To develop and evaluate a slow-release formulation of methotrexate for intracavitary administration.
  • To assess the stability, release kinetics, and in vivo efficacy of the novel formulation.
  • To compare the therapeutic performance of the slow-release formulation against standard methotrexate.

Main Methods:

  • Encapsulation of methotrexate into a lipid-based drug-delivery system (Depo/methotrexate).
  • In vitro stability testing at 4°C and drug release studies in human plasma at 37°C.

Related Experiment Videos

  • In vivo pharmacokinetic studies following intraperitoneal injection in mice.
  • Evaluation of efficacy in the L1210 murine leukemia model.

    • Main Results:

    • Depo/methotrexate exhibited stability for over 4 months at 4°C.
    • In vitro, the drug release half-life in human plasma was 40 days.
    • In vivo, Depo/methotrexate showed a significantly longer intraperitoneal apparent half-life (39.6 h) compared to standard methotrexate (0.5 h).
    • In the L1210 leukemia model, Depo/methotrexate demonstrated 334-fold higher potency, a 2-fold greater increased life-span, and a 2-fold higher therapeutic index.

    Conclusions:

    • Lipid-based encapsulation creates a stable, slow-release formulation of methotrexate suitable for intracavitary administration.
    • Depo/methotrexate significantly enhances the pharmacokinetic profile and therapeutic efficacy in a murine leukemia model.
    • This novel formulation holds promise for improved cancer treatment by optimizing methotrexate delivery and reducing systemic toxicity.